A Phase II Clinical Study to evaluate the efficacy and safety of NRC-2694-A in patients with recurrent Head and Neck Squamous Cell Carcinoma
Latest Information Update: 12 Nov 2019
At a glance
- Drugs NRC 2694A (Primary) ; Carboplatin; Cisplatin; Fluorouracil
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Natco Pharma
Most Recent Events
- 25 Sep 2019 New trial record